Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Inclusion Criteria: * Patients must have a histologically documented (either primary or metastatic site) diagnosis of locally advanced, recurrent, or metastatic ALK rearranged non-small cell lung cancer (NSCLC) * Patients must have shown progression on ALK-directed therapy * Note: Patients may have received more than one prior line of therapy, however, at least one of these must be an ALK-directed line of therapy * Patients must have measurable disease as per appropriate guidelines by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 * Patients must have the ability to understand and the willingness to sign a written consent prior to registration in the study * Patients with asymptomatic (as determined by the treating investigator) CNS metastasis are eligible for participation * Note: Patients with leptomeningeal disease are not eligible * Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * Patient life expectancy of more than 12 weeks * Patients must have adequate organ and bone marrow function during screening, as defined below: * Absolute neutrophil count \>= 1.5 x 10\^9/L * Hemoglobin \>= 9 g/dL * Note: Transfusions are permitted (transfusions \>= 1 day to registration are allowed) * Platelets \>= 75 x 10\^(9)/L * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * Note: Patients with Gilbert syndrome are exempt * Alanine amino transferase and aspartate aminotransferase =\< 2.5 x ULN * No…